Evaluation of dolutegravir and bictegravir based antiretroviral regimens utilization in patients who cannot take medications by mouth

Abstract A retrospective review of intensive care patients unable to take antiretrovirals by mouth showed 56.6% of patients experiencing a transient interruption in therapy. Additionally, our case series further supports previous literature on crushing dolutegravir- and bictegravir-regimens to maintain and achieve viral suppression.